Avatrombopag (Doptelet®) accepted for use within NHS Scotland for treatment of severe thrombocytopenia in adult patients with chronic liver disease scheduled to undergo an invasive procedure

Approval is based on two phase III studies which showed avatrombopag was superior to placebo for proportion of patients who did not require a platelet transfusion or any rescue procedure for bleeding after randomisation and up to 7 days following the procedure.

Scottish Medicines Consortium